• High Capture Efficiency

  Captures 90%+ of rare cells across multiple cancer types

• High Viability

  Over 95%+ cell viability, suitable for various downstream applications such as testing, culture, and drug sensitivity

• High Clinical Sensitivity

  Validated with 1000+ clinical samples, achieving 95%+ clinical sensitivity across cancer types

• Fully Automated

  Completes cell enrichment and purification in 15 mins, with AI software for precise identification and counting

• Circulating Tumor Cells（CTCs）

  Used for early tumor screening, efficacy monitoring, recurrence risk assessment, and subsequent analysis

• Rare Immune Cells

  Supports the enrichment and analysis of specific immune cell subsets, used for immune status evaluation, immunotherapy-related research, and subsequent phenotypic/functional analysis

• Stem Cell-Related Rare Cells

  Based on differences in cellular physical properties, used for cell culture, differentiation observation, functional research, and quality assessment applications

• Fetal-Derived Rare Cells

  Such as low-abundance fetal cells in maternal peripheral blood, used for prenatal-related testing and risk assessment, and can be further analyzed genetically

The company's core products have obtained relevant domestic and international filings and certifications.

NMPA（中国）备案

FDA（美国）备案

CE（欧盟）备案